Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab PoC in Psoriatic Arthritis
NCT00809614Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2009
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of secukinumab in psoriatic arthritis (PsA), sponsored by Novartis. Started Mar 2009; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT00809614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00809614.